Yahoo
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update OVATION 2 Translational Data Presented at ESMO On June 18, 2025, Imunon, Inc. (NASDAQ:IMNN) announced the presentation of translational data from the OVATION 2 clinical trial of IMNN-001 at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025. These results complement the overall
Yahoo
ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-cancer immune cytokines in the tumor-microenvironment post-treatment Company currently advancing Phase 3 pivotal trial of IMNN-001, with first two sites initiated LAWRENCEVILLE, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage
Yahoo
Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform’s potential as a next-generation va
Yahoo
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor
Yahoo
The IMNN-001 arm exhibited a median 13-month increase in OS and a median three-month increase in PFS.
Yahoo
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations LAWRENCEVILLE, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company i
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EJAN | <0.01% | $111.38M | 0.89% |
YLD | -0.01% | $316.23M | 0.39% |
XONE | -0.02% | $585.86M | 0.03% |
TDTT | 0.03% | $2.63B | 0.18% |
NANC | 0.04% | $220.31M | 0.74% |
DEM | 0.06% | $3.04B | 0.63% |
FDN | 0.06% | $7.19B | 0.49% |
GREK | 0.09% | $284.18M | 0.57% |
EEM | 0.11% | $18.20B | 0.72% |
EMXF | -0.11% | $101.54M | 0.17% |
CIBR | -0.14% | $9.92B | 0.59% |
CPNJ | -0.14% | $48.34M | 0.69% |
TMFC | -0.14% | $1.47B | 0.5% |
LONZ | 0.15% | $738.20M | 0.63% |
FLKR | 0.15% | $163.28M | 0.09% |
FXY | 0.15% | $815.67M | 0.4% |
SCHO | -0.16% | $11.46B | 0.03% |
REMX | 0.17% | $290.89M | 0.58% |
JMST | 0.17% | $4.06B | 0.18% |
QCLN | -0.17% | $404.96M | 0.56% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | 33.52% | $827.49M | 0.14% |
URA | 18.28% | $3.73B | 0.69% |
URNJ | 17.25% | $304.99M | 0.8% |
KIE | 16.40% | $835.00M | 0.35% |
URNM | 16.37% | $1.74B | 0.75% |
FDL | 15.86% | $5.39B | 0.43% |
DIV | 15.46% | $642.76M | 0.45% |
XMLV | 15.35% | $809.48M | 0.25% |
PEY | 15.33% | $1.09B | 0.53% |
FXG | 15.08% | $296.12M | 0.63% |
PBDC | 14.94% | $220.97M | 13.94% |
BIZD | 14.93% | $1.57B | 12.86% |
HDV | 14.66% | $10.90B | 0.08% |
VNLA | 14.66% | $2.62B | 0.23% |
CDC | 14.65% | $728.75M | 0.42% |
DHS | 14.38% | $1.22B | 0.38% |
LVHD | 14.19% | $561.47M | 0.27% |
IAK | 14.09% | $807.50M | 0.39% |
SHAG | 14.05% | $43.02M | 0.12% |
SPHD | 14.04% | $3.13B | 0.3% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QXO | -37.26% | $11.99B | -71.11% | 0.00% |
BAH | -31.00% | $12.76B | -33.16% | 2.06% |
WWD | -23.56% | $14.63B | +41.05% | 0.43% |
AMKR | -21.48% | $5.23B | -46.35% | 1.54% |
CPRT | -20.51% | $46.59B | -11.04% | 0.00% |
MNSO | -19.18% | $5.50B | -6.55% | 3.31% |
WDAY | -19.15% | $63.38B | +6.18% | 0.00% |
RCKT | -18.21% | $272.58M | -88.25% | 0.00% |
MRK | -16.10% | $198.62B | -36.11% | 4.04% |
LDOS | -15.81% | $20.04B | +6.72% | 1.01% |
UMC | -15.63% | $19.29B | -12.33% | 12.24% |
MBIN | -15.16% | $1.53B | -17.61% | 1.12% |
ECL | -14.74% | $75.83B | +12.37% | 0.95% |
SYM | -14.37% | $4.06B | +5.94% | 0.00% |
LITB | -14.18% | $21.70M | -78.27% | 0.00% |
YALA | -13.72% | $917.35M | +51.21% | 0.00% |
DECK | -13.60% | $15.57B | -35.41% | 0.00% |
PSN | -13.60% | $7.54B | -13.74% | 0.00% |
NVAX | -13.23% | $1.03B | -49.68% | 0.00% |
ROST | -13.18% | $41.83B | -11.99% | 1.20% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
STOT | -13.09% | $253.88M | 0.45% |
WEAT | -10.71% | $117.15M | 0.28% |
IBTF | -9.18% | $2.02B | 0.07% |
JUCY | -8.78% | $271.76M | 0.6% |
PALL | -8.61% | $494.87M | 0.6% |
CORN | -7.93% | $44.21M | 0.2% |
KCCA | -6.95% | $104.88M | 0.87% |
KSA | -6.76% | $685.02M | 0.75% |
TBLL | -6.47% | $2.14B | 0.08% |
KRBN | -6.28% | $163.57M | 0.85% |
FTXL | -6.26% | $274.60M | 0.6% |
SMH | -6.05% | $25.84B | 0.35% |
IVOL | -5.81% | $351.30M | 1.02% |
SOXQ | -5.61% | $508.57M | 0.19% |
CRPT | -5.61% | $138.36M | 0.85% |
PSI | -5.48% | $716.58M | 0.56% |
BSCP | -5.22% | $3.28B | 0.1% |
BLCN | -5.07% | $46.71M | 0.68% |
TUR | -4.98% | $156.23M | 0.59% |
KBA | -4.96% | $176.19M | 0.56% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PLOW | 35.54% | $673.07M | +23.93% | 4.04% |
HSII | 30.65% | $918.86M | +41.10% | 1.34% |
VRNS | 30.09% | $5.63B | +4.77% | 0.00% |
CVLT | 29.58% | $7.69B | +43.40% | 0.00% |
DOUG | 29.30% | $210.31M | +104.31% | 0.00% |
INFA | 28.75% | $7.36B | -21.47% | 0.00% |
SEG | 27.30% | $227.61M | -30.38% | 0.00% |
LGIH | 27.03% | $1.21B | -42.38% | 0.00% |
CNO | 26.13% | $3.81B | +38.71% | 1.68% |
GORV | 26.05% | $25.03M | -91.07% | 0.00% |
HLIT | 26.05% | $1.07B | -19.37% | 0.00% |
BFS | 26.05% | $825.99M | -7.23% | 6.88% |
BRX | 25.69% | $7.97B | +12.82% | 4.30% |
HOLX | 25.33% | $14.49B | -12.44% | 0.00% |
FFIV | 25.26% | $16.99B | +71.72% | 0.00% |
FISI | 24.22% | $521.24M | +34.16% | 4.69% |
KRG | 24.17% | $4.98B | +1.30% | 4.61% |
HWM | 24.09% | $74.64B | +138.18% | 0.20% |
PECO | 24.00% | $4.38B | +6.70% | 3.49% |
TENB | 23.38% | $4.01B | -24.74% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VIR | <0.01% | $714.69M | -41.91% | 0.00% |
BALL | <0.01% | $15.65B | -6.01% | 1.42% |
ALNT | -<0.01% | $608.09M | +42.14% | 0.33% |
OI | 0.01% | $2.33B | +35.31% | 0.00% |
UBER | -0.01% | $191.40B | +25.94% | 0.00% |
IDCC | -0.01% | $5.99B | +98.12% | 0.81% |
LIF | -0.01% | $4.75B | +91.77% | 0.00% |
CRUS | -0.02% | $5.44B | -16.98% | 0.00% |
IREN | -0.02% | $3.37B | +24.00% | 0.00% |
KNF | -0.02% | $4.69B | +18.01% | 0.00% |
AAPL | 0.02% | $3.00T | -4.53% | 0.50% |
FATE | -0.02% | $119.22M | -68.29% | 0.00% |
SFIX | -0.02% | $460.62M | -14.94% | 0.00% |
IRS | 0.03% | $1.08B | +63.38% | 7.20% |
MSIF | -0.03% | $769.00M | +36.08% | 6.63% |
ACET | -0.03% | $51.74M | -48.30% | 0.00% |
S | -0.03% | $5.93B | -15.20% | 0.00% |
AIP | -0.04% | $406.76M | +29.03% | 0.00% |
PAYS | -0.04% | $384.95M | +64.73% | 0.00% |
WCC | 0.04% | $9.05B | +16.99% | 0.93% |
Current Value
$0.761 Year Return
Current Value
$0.761 Year Return